Investment
Features
FeesSafety
Academy
More
Pluang+

Compare US Global Jets ETF (JETS) vs McKesson Corporation (MCK) Price & Performance

US Global Jets ETFTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

US Global Jets ETF vs McKesson Corporation — how do they compare? US Global Jets ETF trades at $27.25 (market cap $878.48M), while McKesson Corporation trades at $936.01 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 123.5× US Global Jets ETF's market cap, and McKesson Corporation pays a 0.4% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and McKesson Corporation for 74 Days on average.

JETSMCK
Market Cap
$878.48M$108.46B
Volume
4,465,925712,607
Sector
Sector/ThematicHealth
52-Week High
$33.53$995.69
52-Week Low
$23.64$725.17
Typical Hold Time
26 Days74 Days
Enterprise Value
—$115.00B
Dividend Yield
—0.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

US Global Jets ETF

JETS (U.S. Global Jets ETF) trades at $27.67, down 1.53% with a bearish technical outlook. The ETF faces headwinds from rising fuel costs and geopolitical tensions impacting airline profitability. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, though RSI suggests potential oversold conditions. Recent news highlights competitive pressure from defense-focused aerospace ETFs that have outperformed JETS on total returns.

The outlook remains challenging with fuel cost volatility and competitive ETF alternatives presenting risks. However, oversold technical conditions and potential travel demand recovery offer selective opportunities for investors seeking airline exposure. Key catalysts include fuel price stabilization and holiday travel trends.

McKesson Corporation

McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.

The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JETS

No sentiment data available yet.

MCK
40% Buy60% Sell
Avg holding period · 74 Days

Top news

Latest headlines on both assets

About US Global Jets ETF

JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.

Read more on JETS →

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK →